Subject:
- Active Sustance: Eravacyclin
- Name: Xerava®
- Therapeutic area: Complicated intra-abdominal infections (cIAI)
- Pharmaceutical company: PAION Deutschland GmbH
Time table:
- Start: 01.08.2022
- Final decision by G-BA: 19.01.2023
Final decision:
- Additional benefit proved